Cargando…
The Sigma‐2 Receptor/TMEM97 Agonist PB28 Suppresses Cell Proliferation and Invasion by Regulating the PI3K‐AKT‐mTOR Signalling Pathway in Renal Cancer
Sigma‐2 receptor/TMEM97 is overexpressed in many tumours, and sigma‐2 receptor ligands are under investigation for cancer therapy. We intended to evaluate the effect of PB28 on renal cancer in proliferation, migration and invasion in vitro and in vivo. Invasive renal cancer cell lines treated with P...
Autores principales: | Zhan, Bo, Zhang, Zhe, Piao, Chiyuan, Dong, Xiao, Du, Yang, Kong, Chuize, Jiang, Yuanjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650047/ https://www.ncbi.nlm.nih.gov/pubmed/34783163 http://dx.doi.org/10.1111/jcmm.17047 |
Ejemplares similares
-
Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor
por: Liu, Chia-Chi, et al.
Publicado: (2019) -
METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression
por: Liu, Zhuonan, et al.
Publicado: (2021) -
Sigma-2 Receptor Ligand Binding Modulates Association between TSPO and TMEM97
por: Thejer, Bashar M., et al.
Publicado: (2023) -
Small-Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes
por: Oyer, Halley M., et al.
Publicado: (2019) -
TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death
por: Zeng, Chenbo, et al.
Publicado: (2019)